Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Prevail Therapeutics

- PMLiVE

EC approves BioMarin’s gene therapy Roctavian for severe haemophilia A

Approximately 20,000 adults are affected by haemophilia A across more than 70 countries in Europe, the Middle East and Africa

- PMLiVE

Eli Lilly to make bebtelovimab commercially available to US states from August

The COVID-19 antibody is expected to become commercially available prior to the anticipated depletion of the US government’s current available supply

- PMLiVE

Sarepta to submit application for Duchenne muscular dystrophy gene therapy

The condition occurs in approximately one in every 3,500-5,000 newborn males worldwide

- PMLiVE

Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab

The antibody drug treatment has thus far only been authorised for emergency use by the FDA to treat COVID-19 in specific emergency cases in non-hospital settings

- PMLiVE

Eli Lilly’s Verzenios recommended by NICE as combination therapy for early-stage breast cancer

The trial results showed a drop of 32% in cancer recurrence when using Verzenios in combination with endocrine therapy

- PMLiVE

Eli Lilly and Incyte’s Olumiant receives FDA approval for alopecia

The treatment is the first and only systemic medicine for adults with the condition

- PMLiVE

Eli Lilly announces $2.1bn investment in new manufacturing sites

The new sites will create around 500 jobs within the company

- PMLiVE

Eli Lilly and Incyte’s Olumiant approved by FDA for hospitalised COVID-19 patients

Nearly one million people with COVID-19 have been treated with Olumiant in approximately 15 countries worldwide

- PMLiVE

bluebird bio maintains its focus on gene therapy opportunities during structural changes

The company plans to reduce its workforce amid efforts to reduce its operating costs

- PMLiVE

Novartis and Voyager Therapeutics agree on gene therapy deal worth 1.7bn

The licence option agreement is for next-generation gene therapy vectors for neurological diseases

- PMLiVE

bluebird bio shares therapy updates for 2022

The company provided information for its first two gene therapies and its lovo-cel BLA submission for sickle cell disease

- PMLiVE

Results from trial show Eli Lilly’s COVID-19 drug improves survival rates

The RECOVERY trial is the biggest study of COVID-19 treatments in the world, involving more than 47,000 participants in the UK

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links